Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$236.48 USD
+2.19 (0.93%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $236.63 +0.15 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 321 - 340 ( 418 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Strategic Corporate Restructuring To Focus on Key Pipeline Opportunities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Files Phase I Clinical Trial Application for ALN-TTR02
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Files Phase I Clinical Trial Application for ALN-TTR02
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Preliminary Phase I Results for ALN-PCS
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Preliminary Phase I Results for ALN-PCS
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Data for its Hematology Programs at ASH and Regulus Initiates a Brain Cancer Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Data for its Hematology Programs at ASH and Regulus Initiates a Brain Cancer Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Key Opinion Leader?s Thoughts on the State of ATTR and Alnylam?s ALN-TTR Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Key Opinion Leader?s Thoughts on the State of ATTR and Alnylam?s ALN-TTR Program
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Recent Advancements and Strong Forward Momentum
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conversation with Alnylam CEO Highlights Recent Advancements and Strong Forward Momentum
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Completes Enrollment in Phase IIb Study of ALN-RSV01 for RSV Infection
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Completes Enrollment in Phase IIb Study of ALN-RSV01 for RSV Infection
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer Acquisition of Excaliard Pharmaceuticals Sets Rock-bottom Valuation for Regulus Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer Acquisition of Excaliard Pharmaceuticals Sets Rock-bottom Valuation for Regulus Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M